Medicines for Malaria Venture (MMV)

Appeler Itinéraire Site Web

Medicines for Malaria Venture (MMV) A leading PDP working to reduce the burden of malaria in disease-endemic countries.

Progress on gender equality is not inevitable. It has to be sustained. For the fifth consecutive year, MMV has been reco...
22/10/2026

Progress on gender equality is not inevitable. It has to be sustained.

For the fifth consecutive year, MMV has been recognized as a “Very High Performer” in the Global Health 50/50 2026 Gender & Health Index, the highest rating possible.

The index assesses nearly 200 global health organizations, and MMV received a positive assessment across all eight categories, including workplace gender equality policies, leadership representation and sex-disaggregated data.

Five consecutive years of recognition reflect our ongoing commitment to putting our values into practice: making gender equality and inclusion integral to how we work, and bringing together different perspectives and expertise to strengthen the science and partnerships bringing us closer to a -free future.

Explore the full report, including MMV's scorecard: bit.ly/4itEm5H

New treatment regimens for relapsing are giving countries opportunities to simplify care and reduce onward transmissio...
21/10/2026

New treatment regimens for relapsing are giving countries opportunities to simplify care and reduce onward transmission. But how can we ensure these innovations reach the people who need them?

Tomorrow, 22 October, join the Australian Centre of Research Excellence in Malaria Elimination for a webinar exploring the implementation of single-dose tafenoquine, including the challenges countries face in introducing new treatments and how to overcome them.

MMV's Dr Caroline Lynch will join a panel of experts from Menzies School of Health Research, World Health Organization and other partners to discuss the path forward and how to make the most of tafenoquine's potential to support elimination.

Register for this free webinar and see you there: bit.ly/4hX3ujQ

A infection during pregnancy can turn a time of joyful anticipation into one of fear and uncertainty. For women living...
20/10/2026

A infection during pregnancy can turn a time of joyful anticipation into one of fear and uncertainty.

For women living in endemic regions, particularly in remote communities where reaching a healthcare facility may already be difficult, that uncertainty can be especially distressing.

Malaria during pregnancy can have serious consequences for both mother and baby. And when evidence is limited, treatment decisions become more difficult for healthcare providers and families alike.

A new knowledge portal from World Health Organization brings together practical resources to support the responsible inclusion of pregnant and breastfeeding women in clinical trials. The portal provides guidance and tools to help researchers generate the evidence needed for more informed treatment decisions.

Explore the portal and learn how it can help close longstanding evidence gaps in clinical research involving pregnant and breastfeeding women: bit.ly/3Wayd5E

Live from the MMV Latin America Regional Meeting, where national malaria programmes, researchers and partners have conve...
16/10/2026

Live from the MMV Latin America Regional Meeting, where national malaria programmes, researchers and partners have convened to explore how we can sustain progress towards elimination across Latam.

This meeting is an opportunity to share progress and experiences, explore emerging and discuss how countries can make the most of the tools available to them.

Together, we’re strengthening the connections between evidence, policy and implementation.

TIME has named MMV and deepmirror's AI-powered Drug Design for Global Health (dd4gh) platform among its Best Inventions...
16/10/2026

TIME has named MMV and deepmirror's AI-powered Drug Design for Global Health (dd4gh) platform among its Best Inventions of 2026!

dd4gh responds to two pressing needs central to MMV's work: accelerating the discovery of new medicines for and neglected diseases, and broadening access to the technologies that can help scientists in affected countries lead the development of new treatments.

Co-created with researchers from disease-endemic countries, dd4gh is already putting that ambition into practice. Just months after its launch, the majority of its registered users are from low- and middle-income countries.

Read the press release: bit.ly/4zu143h

From crisis to resilience. That was the ambition behind this year's World Health Summit in Berlin. But what will it take...
14/10/2026

From crisis to resilience. That was the ambition behind this year's World Health Summit in Berlin. But what will it take to get there?

For us, part of the answer lies in how we support global health innovation: building on the partnerships and expertise that have delivered new health tools, while giving countries greater leadership in defining the priorities and solutions that matter to them.

Across three days of discussions with governments, researchers, funders and fellow product development partnerships (PDPs), we've explored how the PDP model can evolve to meet this moment and continue delivering the innovations needed to respond to changing global health needs.

As we leave Berlin, let's keep building on this momentum, finding new ways to work together and making the most of the expertise, ideas and capabilities we already have.

A big thank you to everyone who joined us at , engaged in the exchanges we helped facilitate and invited us to contribute to their discussions.

At a time of profound change for global health, the path forward will depend on our ability to work differently – across...
12/10/2026

At a time of profound change for global health, the path forward will depend on our ability to work differently – across sectors, geographies and institutions – and turn shared ambition into collective action.

On the sidelines of the World Health Summit in Berlin, Drugs for Neglected Diseases initiative (DNDi), Global Antibiotic R&D Partnership (GARDP) and MMV convened partners for an open and forward-looking discussion on how collaboration can help sustain health innovation, strengthen local capabilities, and accelerate access to the treatments people need.

The evening reinforced a clear message: progress will require stronger partnerships, bold choices, and long-term commitment. Together, we must create the conditions for needs-driven research and development, mobilize new sources of financing, and ensure that equity and access are built into innovation from the outset.

Our sincere thanks to all our guests for joining us and contributing their perspectives, experience, and ideas. We are especially grateful to our speakers for setting the tone for such a thoughtful and energizing exchange.

The conversations must now translate into deeper cooperation and practical action for a healthier, more equitable and resilient future.

Global health is evolving, and so are we.Today, Drugs for Neglected Diseases initiative (DNDi), Medicines Development fo...
12/10/2026

Global health is evolving, and so are we.

Today, Drugs for Neglected Diseases initiative (DNDi), Medicines Development for Global Health, MMV and TB Alliance published a joint paper on how research, innovation and product development can help build a more sovereign, resilient and equitable future for health.

Countries are leading on their health priorities. We are working with them to put that leadership at the centre of how new health tools are developed: shifting the centre of gravity towards country and regional ownership, reducing duplication without losing specialization, focusing on people-centred R&D, and evolving to increase efficiency and equity.

Drawing on 27 years of experience and 40 new therapeutics, we are ready to keep building, with countries and partners leading.

Read the paper and join the conversation: bit.ly/4enkZsr

Global health has no shortage of ambition. The challenge is creating the conditions that allow to turn that ambition i...
12/10/2026

Global health has no shortage of ambition. The challenge is creating the conditions that allow to turn that ambition into impact.

At the World Health Summit in Berlin, MMV and fellow product development partnerships (PDPs) brought together governments, funders, industry and global health organizations to discuss how the PDP model can help make global health innovation more effective and sustainable.

PDPs connect expertise and resources across sectors and countries to develop medicines, vaccines and other health tools where traditional market incentives fall short.

As the model evolves, PDPs are finding new ways to combine capabilities, strengthen country leadership and respond to changing health priorities.

By building on what works and helping define new ways of working, PDPs can accelerate the development of the life-saving innovations people need.

Thank you to everyone who contributed to the discussion, and to our co-hosts Drugs for Neglected Diseases initiative (DNDi), IVCC (Innovative Vector Control Consortium), PATH, Population Council and TB Alliance for bringing this important conversation to the World Health Summit.

Where medicines are made has a direct impact on who can access them. The vast majority of cases and deaths occur in Af...
08/10/2026

Where medicines are made has a direct impact on who can access them.

The vast majority of cases and deaths occur in Africa, yet the continent remains heavily reliant on imports for the medicines needed to fight the disease.

A new Access to Medicine Foundation report looks at how African pharmaceutical manufacturers are expanding the supply and availability of medicines, including through partnerships supporting regional manufacturing capacity.

In Kenya, one such partnership has helped turn local manufacturing capacity into access.

With support from MMV, Universal Corporation Limited achieved WHO prequalification for the malaria prevention medicine SPAQ. Last year, The Global Fund procured 7 million doses from UCL for use in Mali, enough to protect approximately 1.8 million children.

MMV has also partnered with Africa CDC to increase the number of African antimalarial manufacturers meeting WHO prequalification standards, helping create a stronger base for African-made malaria medicines.

The goal? A more resilient supply of quality-assured medicines, closer to the people who need them.

Read the report: bit.ly/4zc2X4m

Adresse

20, Route De Pré-Bois
Geneva
1215

Téléphone

+41 22 555 03 00

Site Web

Notifications

Soyez le premier à savoir et laissez-nous vous envoyer un courriel lorsque Medicines for Malaria Venture (MMV) publie des nouvelles et des promotions. Votre adresse e-mail ne sera pas utilisée à d'autres fins, et vous pouvez vous désabonner à tout moment.

Raccourcis

Partager